(Q30500348)

16 October 2017

Targeting tumor vasculature with an oncolytic virus (English)

1 reference

16 October 2017

1 reference

12

1 reference

16 October 2017

17

John C Bell

1 reference

16 October 2017

Caroline J Breitbach

1

1 reference

16 October 2017

Naomi S De Silva

2

1 reference

16 October 2017

Theresa J Falls

3

1 reference

16 October 2017

Usaf Aladl

4

1 reference

16 October 2017

Laura Evgin

5

1 reference

16 October 2017

Jennifer Paterson

6

1 reference

16 October 2017

Yang Yang Sun

7

1 reference

16 October 2017

Dominic G Roy

8

1 reference

16 October 2017

Julia L Rintoul

9

1 reference

16 October 2017

Manijeh Daneshmand

10

1 reference

16 October 2017

Kelley Parato

11

1 reference

16 October 2017

Brian D Lichty

13

1 reference

16 October 2017

Aaron Fenster

14

1 reference

16 October 2017

David Kirn

15

1 reference

16 October 2017

Harold Atkins

16

1 reference

16 October 2017

1 March 2011

1 reference

16 October 2017

1 reference

16 October 2017

19

1 reference

16 October 2017

5

1 reference

16 October 2017

886-894

1 reference

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Oncolytic viruses: a novel form of immunotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Recent progress in the battle between oncolytic viruses and tumours

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Viral vascular endothelial growth factor plays a critical role in orf virus infection.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Getting oncolytic virus therapies off the ground

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

Mechanisms of endothelial cell injury in acute inflammation.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098639

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364541

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bothroalternin, a thrombin inhibitor from the venom of Bothrops alternatus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364541

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/MT.2011.26

1 reference

16 October 2017

1 reference

16 October 2017

PubMed publication ID

21364541

1 reference